ATTO trades near $20, already 9% below its IPO print, with the entire pipeline built around blocking IL-31, dubbed the 'itch cytokine.' Founded in 2023 and backed by $256 million raised, Attovia's next Phase 1 trial won't start until 2027, leaving commercial revenue years away. It sounds nuts, but SoFi1 is giving new Active Invest users up to $3,000 in stock for a limited time, and all it takes is a $50 deposit to get started.2 See for yourself (Sponsor) Attovia Therapeutics (NASDAQ:ATTO) has arrived on public markets with a pipeline built entirely on one bet: that a biparatopic antibody platform called Attobody can turn well-validated immunology targets into next-generation biologics. The lead asset is aimed at the cytokine behind chronic itch.
Shares last changed hands at $19.86, up 3.6% on the session, giving Attovia a market capitalization of roughly $287.9 million. With only eight trading days of history, the stock has drifted 9.32% lower from its $21.90 early print. The centerpiece is ATTO-1310.
Per the S-1, it is a "novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31" and is currently in a Phase 1 clinical trial in healthy volunteers and patients. Attovia is developing it for chronic pruritus and high-itch atopic dermatitis, positioning against a cytokine the filing describes it thus: "IL-31 commonly known as the 'itch cytokine.' IL-31 upregulated in host of pruritic diseases." The label ambition extends to chronic pruritus of unknown origin and cholestatic pruritus in primary biliary disease. Attobody was in-licensed from Alamar Biosciences and uses an evolution-driven, high-throughput process to generate biparatopic biologics.
Behind ATTO-1310 sit two additional candidates: SoFi Active Invest is offering a limited-time promotion. Open an account, fund it with $50 or more, and you could receive up to $3,000 in complimentary stock for Active Invest accounts. See for yourself by clicking here now.
ATTO-2306: a bispecific targeting IL-13 and IL-31, in IND-enabling studies, with a Phase 1 trial expected to commence in the first half of 2027. ATTO-1091: a trispecific Attobody-based Fc fusion protein designed to block TL1A, IL-23 and integrin a4ß7 simultaneously, aimed at inflammatory bowel disease. The company, founded in 2023, disclosed it raised $255.8 million as of March 31, 2026.
That runway that included a $90 million Series C reported ahead of the offering. Underwriters on the IPO include Morgan Stanley, Leerink Partners, Citigroup, RBC Capital Markets, and LifeSci Capital. Attovia is classified as an emerging growth company and smaller reporting company, meaning reduced disclosure requirements.
Extract — continue reading at the source.
